Main Contact: Ms. Catalina Loveman
Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines to meet serious unmet medical needs in oncology and inflammation and autoimmunity. Incyte’s drug discovery activities were initiated in 2002 on the belief that investments in innovation create value. Incyte remains committed to the rigorous pursuit of R&D excellence to improve the lives of patients, make a difference in health care, and build sustainable value for its stakeholders. The Company strives to discover and develop first-in-class and best-in-class medicine and is advancing a diverse portfolio of large and small molecules. Headquartered in Wilmington, Delaware, Incyte has offices in Switzerland, nine other European countries and Japan. For more information, visit www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte.
- Established in 2002
- Foreign Locations
- Publicly Owned
- Member Since 2019